These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 34965958)
41. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents. El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381 [TBL] [Abstract][Full Text] [Related]
42. Histone deacetylase inhibitors in the treatment for multiple myeloma. Hideshima T; Anderson KC Int J Hematol; 2013 Mar; 97(3):324-32. PubMed ID: 23475757 [TBL] [Abstract][Full Text] [Related]
43. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499 [TBL] [Abstract][Full Text] [Related]
44. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307 [TBL] [Abstract][Full Text] [Related]
45. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling. Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742 [TBL] [Abstract][Full Text] [Related]
46. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689 [TBL] [Abstract][Full Text] [Related]
47. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Singh AK; Bishayee A; Pandey AK Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797 [TBL] [Abstract][Full Text] [Related]
48. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Bush EW; McKinsey TA Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912 [TBL] [Abstract][Full Text] [Related]
49. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs). Linciano P; Benedetti R; Pinzi L; Russo F; Chianese U; Sorbi C; Altucci L; Rastelli G; Brasili L; Franchini S Bioorg Chem; 2021 Jan; 106():104462. PubMed ID: 33213894 [TBL] [Abstract][Full Text] [Related]
51. Development and therapeutic impact of HDAC6-selective inhibitors. Dallavalle S; Pisano C; Zunino F Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920 [TBL] [Abstract][Full Text] [Related]
52. Targeting class I histone deacetylases in cancer therapy. Delcuve GP; Khan DH; Davie JR Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071 [TBL] [Abstract][Full Text] [Related]
53. Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Richon VM Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904 [TBL] [Abstract][Full Text] [Related]
54. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Chun P Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088 [TBL] [Abstract][Full Text] [Related]
55. Therapeutic potential for HDAC inhibitors in the heart. McKinsey TA Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627 [TBL] [Abstract][Full Text] [Related]